This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Pieter M. ter Wee, MD; Anna G. De Micheli, MD; Murray Epstein, MD

Arch Intern Med. 1994;154(11):1185-1202.

Abstract
In recent years, substantial investigative attention has focused on therapeutic regimens that could retard the progression of chronic renal insufficiency. Emphasis has been placed on the effects of antihypertensive treatment on renal hemodynamics and preservation of renal function. It has been suggested that some classes of antihypertensive agents may confer a greater renoprotective effect, especially agents that lower glomerular capillary pressure. Conversely, by virtue of their ability to preferentially dilate the afferent arteriole calcium antagonists theoretically could favor an increase in glomerular capillary pressure thereby accelerating the decline of renal function. In this review we survey the literature critically and conclude that in patients with essential hypertension and in patients with chronic renal insufficiency, calcium antagonists effectively reduce systemic blood pressure while maintaining glomerular filtration rate and effective renal plasma flow. Preliminary results from a few long-term studies suggest that calcium antagonists may even attenuate the decline in renal function of patients with chronic renal failure. The majority of studies in humans, however, have been nonrandomized, of too short duration, or confounded by investigative difficulties precluding definite conclusions whether calcium antagonists have renoprotective effects. Although the possibility that calcium antagonists may retard progression of renal disease remains to be ascertained, the available evidence indicates that calcium antagonists may be used in patients with renal functional impairment without further exacerbating renal function. (Arch Intern Med. 1994;154:1185-1202)

Author Affiliations
From the Nephrology Section, Department of Veterans Affairs Medical Center, Miami, Fla (Dr Epstein) and Division of Nephrology (Drs ter Wee, De Micheli, and Epstein), Veterans Affairs Medical Center and University of Miami School of Medicine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Blood Pressure Control, Drug Therapy, and Kidney Disease
Contreras et al.
Hypertension 2005;46:44-50.
ABSTRACT | FULL TEXT  

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHA
JAMA 2002;288:2981-2997.
ABSTRACT | FULL TEXT  

Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial
Wright et al.
JAMA 2002;288:2421-2431.
ABSTRACT | FULL TEXT  

Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial
Agodoa et al.
JAMA 2001;285:2719-2728.
ABSTRACT | FULL TEXT  

Hypertensive nephrosclerosis: pathogenesis and prevalence : Essential hypertension is an important cause of end-stage renal disease
Luke
Nephrol Dial Transplant 1999;14:2271-2278.
FULL TEXT  

Current Strategies for Management of Hypertensive Renal Disease
Moore et al.
Arch Intern Med 1999;159:23-28.
ABSTRACT | FULL TEXT  

Chronic Renal Insufficiency: A Diagnostic and Therapeutic Approach
Rahman and Smith
Arch Intern Med 1998;158:1743-1752.
ABSTRACT | FULL TEXT  

Fixed Low-Dose Drug Combination for the Treatment of Hypertension
Chrysant
Arch Fam Med 1998;7:370-376.
ABSTRACT | FULL TEXT  

Diuretic-Based Treatment and Cardiovascular Events in Patients With Mild Renal Dysfunction Enrolled in the Systolic Hypertension in the Elderly Program
Pahor et al.
Arch Intern Med 1998;158:1340-1345.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Nifedipine Coat-Core versus Amlodipine in Patients With Mild to Moderate Essential Hypertension: Comparison of 24-Hour Mean Ambulatory Diastolic Blood Pressure
Byyny et al.
J CARDIOVASC PHARMACOL THER 1997;2:77-83.
ABSTRACT  

1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension
National High Blood Pressure Education Program Wor
Arch Intern Med 1996;156:1938-1947.
ABSTRACT  

Newer Approaches to Antihypertensive Therapy: Use of Fixed-Dose Combination Therapy
Epstein and Bakris
Arch Intern Med 1996;156:1969-1978.
ABSTRACT  

Renal Parenchymal Hypertension: Current Concepts of Pathogenesis and Management
Preston et al.
Arch Intern Med 1996;156:602-611.
ABSTRACT